Potential approval of a high value complex generic on the same lines as gRevlimid can be a positive surprise, adds the brokerage.

Revenue grew 11.4% to Rs 8,572 crore, but the bottom line of Rs 1,418 crore missed Bloomberg’s consensus estimate of Rs 1,514 crore.

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

The researchers first tested their hypothesis by delivering ODN directly to the hindbrain of rats. Once treated, the rats ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

The FDA has issued a warning as fake Ozempic have started circulating amid a recent trend seeing people using the diabetes ...

Low doses of the injectable weight-loss medication semaglutide may improve symptoms of a hard-to-treat type of heart failure. This effect happened through direct action on the heart muscle and blood ...

Dr. Reddy's Laboratories intends to introduce a more affordable generic version of Novo Nordisk's popular weight-loss ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...